EP Patent

EP0293063A1 — 2-Phenylpurinone derivatives, processes for their preparation, and their use as well as intermediates

Assigned to Smith Kline and French Laboratories Ltd · Expires 1988-11-30 · 37y expired

What this patent protects

Compounds of the formula (1) : and pharmaceutically acceptable salts thereof are described, wherein R¹ is C 1-6 alkyl or C 2-6 alkenyl, and R² is hydrogen or hydroxy. These compounds have vasodilator, bronchodilator and anti-allergic properties. Pharmaceutical composi…

USPTO Abstract

Compounds of the formula (1) : and pharmaceutically acceptable salts thereof are described, wherein R¹ is C 1-6 alkyl or C 2-6 alkenyl, and R² is hydrogen or hydroxy. These compounds have vasodilator, bronchodilator and anti-allergic properties. Pharmaceutical compositions are described as are methods of use. Processes for the preparation of the compounds of the formula (1) are described.

Drugs covered by this patent

Patent Metadata

Patent number
EP0293063A1
Jurisdiction
EP
Classification
Expires
1988-11-30
Drug substance claim
No
Drug product claim
No
Assignee
Smith Kline and French Laboratories Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.